MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecul...

Descripción completa

Detalles Bibliográficos
Autores principales: San José-Enériz, Edurne, Román-Gómez, José, Jiménez-Velasco, Antonio, Garate, Leire, Martin, Vanesa, Cordeu, Lucia, Vilas-Zornoza, Amaia, Rodríguez-Otero, Paula, José Calasanz, María, Prósper, Felipe, Agirre, Xabier
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743636/
https://www.ncbi.nlm.nih.gov/pubmed/19723306
http://dx.doi.org/10.1186/1476-4598-8-69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743636/
https://www.ncbi.nlm.nih.gov/pubmed/19723306
http://dx.doi.org/10.1186/1476-4598-8-69

Ejemplares similares